Management of external cephalic version in France: A national practice survey.


Journal

Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 29 07 2021
revised: 16 09 2021
accepted: 30 09 2021
pubmed: 9 10 2021
medline: 13 1 2022
entrez: 8 10 2021
Statut: ppublish

Résumé

The breech presentation represents 4,7% of deliveries at term. There is a method of external cephalic version (ECV) performed from 36 weeks of gestation. French guidelines for the clinical practice of ECV were published in 2020. To evaluate the national practices of ECV in French maternity units, especially on the use of tocolysis, 1 year after publication of the French clinical recommendations guidelines by the French national college of obstetricians and gynecologists (CNGOF). Data self-reported for this national descriptive study were collected from March to May 2021 by an online questionnaire distributed to all French maternities. The 25 items of the questionnaire collected information of maternity units, the general practice of ECV, use or not of tocolysis for ECV attempt and the relevance of a prospective study. Of the 517 French maternity units, 150 (29%) responded to the online survey.  95,3% systematically performed ECV. A Kleihauer test was routinely performed in 71 units (49.7%). A tocolysis was associated with ECV attempt in 52.4% of cases. The drugs used were intravenous atosiban (30,7%), mainly in levels 2b and 3 maternity units, intravenous salbutamol (24%), other mode of administration of salbutamol (14,7%) and oral nifedipine (22,6%) mainly in levels 1 and 2a maternity units. Adverse effects were described in 20%, mainly with the use of salbutamol (73,3%). 52.4% of the French maternity units surveyed used tocolysis for the ECV attempt, although it is systematically recommended. The choice of tocolytic drug differed according to the maternity units.

Identifiants

pubmed: 34624512
pii: S2468-7847(21)00176-8
doi: 10.1016/j.jogoh.2021.102239
pii:
doi:

Substances chimiques

Tocolytic Agents 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

102239

Informations de copyright

Copyright © 2021. Published by Elsevier Masson SAS.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Any authors have financial competing interests. Vincent Dochez is a regular reviewer of the editorial board. Norbert Winer and Thibault Thubert are associate editors of this journal. The other authors have no non-financial competing interests.

Auteurs

Lise Harendarczyk (L)

Service de Gynécologie-Obstétrique, CHU de Nantes, Nantes, France.

Valéry-Pierre Riche (VP)

Service Evaluation Economique et Développement des Produits de Santé, Département Partenariats et Innovation, Direction de la Recherche, CHU de Nantes, Nantes, France.

Chloé Arthuis (C)

Service de Gynécologie-Obstétrique, CHU de Nantes, Nantes, France; Centre d'Investigation Clinique CIC 1413, INSERM, CHU de Nantes, Nantes, France.

Anne Chauviré-Drouard (A)

Centre d'Investigation Clinique CIC 1413, INSERM, CHU de Nantes, Nantes, France.

Maxime Leroy (M)

Plateforme de Biométries et Biostatistiques, CHU de Nantes, Nantes, France.

Ingrid Bénard (I)

Service Evaluation Economique et Développement des Produits de Santé, Département Partenariats et Innovation, Direction de la Recherche, CHU de Nantes, Nantes, France.

Thibault Thubert (T)

Service de Gynécologie-Obstétrique, CHU de Nantes, Nantes, France; Centre d'Investigation Clinique CIC 1413, INSERM, CHU de Nantes, Nantes, France.

Norbert Winer (N)

Service de Gynécologie-Obstétrique, CHU de Nantes, Nantes, France; Centre d'Investigation Clinique CIC 1413, INSERM, CHU de Nantes, Nantes, France.

Vincent Dochez (V)

Service de Gynécologie-Obstétrique, CHU de Nantes, Nantes, France; Centre d'Investigation Clinique CIC 1413, INSERM, CHU de Nantes, Nantes, France. Electronic address: vincent.dochez@chu-nantes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH